North America Idiopathic Pulmonary Fibrosis Market Size, Share & Industry Trends Analysis Report By Drug Type, By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Providers, By Country and Growth Forecast, 2021-2027

The North America Idiopathic Pulmonary Fibrosis Market is expected to witness market growth of 5.6% CAGR during the forecast period (2021-2027).

Idiopathic pulmonary fibrosis is a sort of chronic scarring lung disease that causes a steady reduction in lung function that's irreversible. In addition, shortness of breath and a persistent dry, hacking cough are the most prevalent indications and symptoms of idiopathic pulmonary fibrosis. Moreover, many people who are impacted also observe a decrease in appetite and weight loss over time. Due to a lack of oxygen, some persons with idiopathic pulmonary fibrosis acquire enlarged and rounded tips of the fingers and toes (clubbing).

While it's difficult to define who develops IPF, some studies showcase that more male women are diagnosed with the disease than females. Age is also a determining factor in IPF. In a vast number of researches, older age has been identified as a prevalent diagnostic factor for IPF.

According to the Centers for Disease Control and Prevention, more than 14% (34.1 million) of adults in the United States smoked tobacco in 2019. As per the American IPF Foundation, the incidence of idiopathic pulmonary fibrosis (IPF) has doubled in the last ten years. In the United States, an estimated 50,000 people die from IPF each year, which is higher than breast cancer.

Moreover, the Centers for Disease Control and Prevention recently discovered a statistically significant cluster of IPF patients diagnosed at a Virginia medical centre. Because of the increased frequency of the condition, as well as the rising geriatric population and smoking habits, the United States is a prominent country of the regional market. In the United States, idiopathic pulmonary fibrosis treatment costs $100,000 per year, according to data published in the American Journal of Managed Care (AJMC) in 2014.

The US market dominated the North America Idiopathic Pulmonary Fibrosis Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $1,269.5 million by 2027. The Canada market is poised to grow at a CAGR of 8% during (2021 - 2027). Additionally, The Mexico market is expected to display a CAGR of 7% during (2021 - 2027).

Based on Drug Type, the market is segmented into Pirfenidone and Nintedanib. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospital Pharmacies, and Online Providers. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GNI Group Ltd., Shionogi & Co., Ltd., Mission Therapeutics Ltd., Galapagos NV, FibroGen, Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Bristol Myers Squibb Company, Boehringer Ingelheim International GmbH, and Biogen, Inc.

Scope of the Study

Market Segments Covered in the Report:

By Drug Type

• Pirfenidone
• Nintedanib

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Providers

By Country: US, Canada, Mexico, and Rest of North America.

Key Market Players

List of Companies Profiled in the Report:

• GNI Group Ltd.
• Shionogi & Co., Ltd.
• Mission Therapeutics Ltd.
• Galapagos NV
• FibroGen, Inc.
• AstraZeneca PLC
• F. Hoffmann-La Roche Ltd.
• Bristol Myers Squibb Company
• Boehringer Ingelheim International GmbH
• Biogen, Inc.

Unique Offerings from the Publisher

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free